Jun. 17 at 6:10 AM
$SLS CDKinase Inhibitors -Blockbusters with Household names.
Gleevic - Imbruvica - Rinvoq
$PFE Ibrance - Palbociclib CDKinase Inhibitor
$NVS Kisqali -Ribociclib CDKinase Inhibitor
$LLY Verzenio - Abemaciclib CDKinase Inhibitor
$SLS Tambiciclib CDKInase Inhibitor.
CDK9 Inhibitors off target toxicity has been the only reason a CDK9 Inhibitor is not yet FDA Approved - Tambiciclib Will BE FDA APPROVED Like Many other Kinase Inhibitors.
- 009 P2B data Not 1 DLT, NOT 1 Serious Side EFFECT - 0 Grade 3 or 4 TRAE's
We Know 009 only needs 25% response rates for Approval, its 50+% for AML-MR patients who've Failed VEN - 13,400 AML-MR DXd each year.
Bottom LINE: TAMBICICLIB Will Be FDA Approved - the Market Has yet to appreciate its value.
